Pfizer Accrued Rebates, Returns, and Promotions increased by 10.9% to $12.94B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.0%, from $12.10B to $12.94B. Over 2 years (FY 2022 to FY 2024), Accrued Rebates, Returns, and Promotions shows an upward trend with a 26.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate higher promotional spending to drive growth or potential quality issues leading to higher return expectations.
This account aggregates liabilities related to customer incentive programs, product return provisions, and promotional m...
Common in consumer-facing healthcare and retail-adjacent medical products; peers with aggressive marketing strategies typically show higher balances.
accrued_rebates_returns_promotions| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.72B | $6.66B | $6.99B | $7.76B | $9.01B | $8.48B | $9.40B | $12.10B | $10.82B | $10.95B | $11.67B | $12.94B |
| QoQ Change | — | -1.0% | +5.0% | +11.0% | +16.2% | -5.9% | +10.8% | +28.7% | -10.5% | +1.1% | +6.6% | +10.9% |
| YoY Change | — | — | — | — | +34.1% | +27.4% | +34.5% | +55.9% | +20.1% | +29.1% | +24.1% | +7.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.